Group 1: Macro Economic Outlook - The report indicates that China's economy is expected to enter a phase of prosperity in 2026, with a strong ability to create wealth reflected in a projected GDP growth of 5.0% for 2025, supported by a 5.5% increase in exports despite global trade barriers [6][7] - Nominal GDP growth is under pressure but shows signs of marginal improvement, with a quarterly growth of 3.8% in Q4 2025, indicating a recovery in cash flow and potential for further recovery in 2026 due to capital repatriation and monetary easing [7][9] - Consumer spending is identified as a key area for growth, with significant potential for recovery as policies to support consumption are expected to be optimized, although the consumer balance sheets remain under pressure [8][11] Group 2: Investment Opportunities - The report maintains a positive outlook on major assets such as AH shares and government bonds, suggesting that A-shares will reach new highs post "spring excitement," with recommended sector allocations in non-ferrous metals, consumer goods, and high-end manufacturing [6][12] - The acquisition of a 11.94% stake in Shengang Securities by Ruida Futures is seen as a strategic move to enhance wealth management capabilities and strengthen the synergy between securities and futures, with a projected net profit increase of 30.1% to 498 million yuan by 2025 [2][15] - In the beauty and healthcare sector, Juzi Bio is positioned for growth with the approval of innovative medical devices, projecting EPS growth from 1.82 yuan in 2025 to 2.46 yuan in 2027, maintaining a "buy" rating [3][19] Group 3: Market Trends and Sector Analysis - The North Exchange market is experiencing a rotation with a focus on sectors like commercial aerospace and technology, suggesting structural opportunities in specialized sectors such as semiconductors and robotics, driven by favorable policies and liquidity changes [4][24] - The report highlights the importance of monitoring liquidity changes and market style shifts, recommending investments in leading companies within sectors that benefit from clear policy support [4][24] - The beauty and healthcare industry is entering a new growth phase driven by technological advancements and a strong product pipeline, with Juzi Bio leveraging its platform for competitive advantage [3][19]

Core Viewpoint - The company has received regulatory approval for two key Class III medical devices, enhancing its position in the recombinant collagen market and addressing diverse aesthetic needs through innovative product offerings [1][2][3]. Group 1: Product Approvals - On January 15, 2026, the company received a Class III medical device registration certificate from the National Medical Products Administration of China for the "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" [1]. - The first approved product, "Recombinant Type I α1 Collagen Lyophilized Fiber," was the first recombinant collagen injection approved in China, designed for treating dynamic facial wrinkles [1]. Group 2: Product Innovation - The newly approved "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" is an injectable pre-mixed solution that combines equal concentrations of recombinant collagen (4.5 mg/mL) and sodium hyaluronate (4.5 mg/mL) [2]. - This product aims to improve skin smoothness through dermal injections, targeting the popular demand for skin quality improvement and hydration [2]. Group 3: Competitive Advantage - The company has established a strong competitive edge through a comprehensive "technology-brand-channel" strategy, supported by its proprietary recombinant collagen and synthetic biology technology platform [3]. - The approval of two Class III medical devices validates the platform's compliance and advanced nature, paving the way for future product expansion [3]. - The dual-brand strategy ("Kefumei" and "Keli Jin") and established hospital channels enhance the penetration of medical aesthetic products, transitioning the brand from skincare to medical-grade [3]. Group 4: Financial Projections - The company projects EPS of 1.82, 2.12, and 2.46 yuan for the years 2025 to 2027, with corresponding latest P/E ratios of 17.2, 14.8, and 12.8 times [3].

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Insights - The company has received approval from the National Medical Products Administration of China for its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution," marking a significant milestone in its product development [1][2]. - The company has successfully launched two key Class III medical devices, enhancing its competitive edge in the recombinant collagen sector [3]. - The dual product strategy addresses both wrinkle reduction and skin quality improvement, catering to diverse consumer needs in the aesthetic medicine market [2][3]. Financial Projections - Revenue is projected to grow from 3,524 million in 2023 to 7,204 million in 2027, with a peak growth rate of 57.2% in 2024 [4]. - Net profit is expected to increase from 1,452 million in 2023 to 2,630 million in 2027, with a notable growth rate of 44.9% in 2023 [4]. - Earnings per share (EPS) are forecasted to rise from 1.49 in 2023 to 2.46 in 2027, reflecting a strong upward trend in profitability [4]. Valuation Metrics - The price-to-earnings (P/E) ratio is projected to decrease from 21.1 in 2023 to 12.8 in 2027, indicating an improving valuation as earnings grow [4]. - The price-to-book (P/B) ratio is expected to decline from 7.2 in 2023 to 2.7 in 2027, suggesting a more favorable valuation relative to book value over time [4].

Core Insights - The company, Juzhi Biotechnology, has received approval for its recombinant type I α1 collagen protein lyophilized fiber, which is indicated for facial dermal tissue filling to correct dynamic wrinkles such as glabellar lines, forehead lines, and crow's feet [1][2]. Product Development - Juzhi Biotechnology has four recombinant collagen injection products under application, including liquid and solid formulations for facial wrinkles and gels for nasolabial folds and neck wrinkles [1]. - The company’s recombinant collagen gel for neck wrinkles has entered the priority approval channel, which is expected to expedite the approval process for its products [2]. Innovation and Patents - The company has received patent authorization for two innovative products: a recombinant type IV collagen composition for sensitive skin care and a fermented ginseng product aimed at cognitive impairment and memory improvement [2]. Financial Projections - Juzhi Biotechnology is a leader in the recombinant collagen sector in China, with projected net profits of 2.566 billion, 3.214 billion, and 4.046 billion yuan for 2025-2027, reflecting year-on-year growth rates of 24%, 25%, and 26% respectively [3]. - The latest closing price corresponds to a price-to-earnings ratio of 16, 12, and 10 for 2025-2027, maintaining a "buy" rating [3].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The approval of the first Class III medical device, recombinant type I collagen, opens new growth avenues in the medical aesthetics sector [7] - The company is a leader in the recombinant collagen field in China, with strong brand and product capabilities, supported by a core technology platform and channel expansion [7] - The company has four additional recombinant collagen injection products under application, with the latest approval expected to catalyze growth [7] - Continuous innovation in research and development is expanding the application boundaries of technology, with recent patent grants enhancing the company's product offerings [7] - Financial forecasts indicate a robust growth trajectory, with projected net profits of 2.57 billion, 3.21 billion, and 4.05 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 24%, 25%, and 26% [7] Financial Summary - Total revenue is projected to grow from 5.54 billion yuan in 2024 to 11.62 billion yuan in 2027, with year-on-year growth rates of 57.17%, 28.60%, 27.20%, and 28.23% respectively [1][8] - The latest diluted EPS is expected to increase from 1.93 yuan in 2024 to 3.78 yuan in 2027, with corresponding P/E ratios decreasing from 19.47 to 9.92 [1][8] - The company maintains a low debt ratio of 18.58%, indicating strong financial health [6]